Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Men receiving treatment for prostate cancer often face challenges that extend well beyond the disease itself. A new study led ...

Researchers have found in a new study that among men with prostate cancer undergoing androgen deprivation therapy, use of oxybutynin 5 mg twice daily significantly reduced the frequency ...

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary therapies, and medication.

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

Bayer AG (BAYRY) announced an update on their ongoing clinical study. The CHINANEO trial is a Phase 2 Bayer study in China testing how well a combo of darolutamide and hormone therapy works before ...

Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...

Two types of androgen deprivation therapy (ADT) had different effects on coronary atherosclerosis in a small randomized trial of men with prostate cancer. Significantly more coronary artery plaque ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.